Genetic Landscape and Biomarkers of Hepatocellular Carcinoma

Keyphrases

• 6p21 20%
• Activation Phenotype 20%
• ARID1A 20%
• ARID2 20%
• Axin1 20%
• B-DNA 20%
• Cancer Causes 20%
• Cancer Mortality 20%
• Chromosome 9 20%
• Copy number Variation 20%
• CTNNB1 20%
• Curative Treatment 20%
• Cyclin-dependent Kinase Inhibitor 2A (CDKN2A) 20%
• Deregulated Pathway 20%
• Differential Enrichment 20%
• DNA Amplification 20%
• DNA Insertion 20%
• Epigenetic Biomarkers 100%
• Fibroblast Growth Factor 19 (FGF19) 20%
• Frequent mutation 20%
• Genetic Landscape 100%
• Genetic Modification 20%
• Genomic Profiling 20%
• Hepatitis B 20%
• Hepatocellular Carcinoma 100%
• Hepatocellular Carcinoma Patients 20%
• Homozygous Deletion 20%
• Kelch-like ECH-associated Protein 1 (Keap1) 20%
• Medical Needs 20%
• MLL2 20%
• Molecular Clusters 20%
• Multikinase Inhibitor 20%
• Mutated Genes 20%
• Non-oncogene Addiction 20%
• Nonproliferation 20%
• Pathway Activation 20%
• Preneoplastic Lesions 20%
• Prognostic Signature 20%
• Prototypic 20%
• RPS6KA3 20%
• Sorafenib 20%
• Telomerase Expression 20%
• TERT Promoter 40%
• Therapeutic Approaches 20%
• Therapeutic Decision-making 20%
• TSC1 20%
• Tuberous Sclerosis Complex 20%
• Tumor Phenotype 20%
• Tumor Protein p53 (TP53) 20%
• Vascular Endothelial Growth Factor 20%
• Western Population 20%

Biochemistry, Genetics and Molecular Biology

• ARID1A 50%
• AXIN1 50%
• Chromosome 9 50%
• Copy-Number Variation 50%
• FGF19 50%
• Gene Amplification 50%
• Gene Insertion 50%
• Gene Mutation 50%
• Genetics 100%
• Genomics 50%
• KEAP1 50%
• MLL2 50%
• Mutated Genes 50%
• Promoter Region 100%
• Sorafenib 50%
• Telomerase 50%
• TSC1 50%
• TSC2 50%